LY2835219

LY2835219, Abemaciclib, is a potent and selective, and orally bioavailable dual inhibitor of CDK4 (cyclin-dependent kinase) and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. In September 2017, Abemaciclib was approved by FDA to treat certain advanced or metastatic breast cancers. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6 can cause cell cycle deregulation as seen in certain types of cancer.


Cat. No.: EX-A521	Purity: >99%

	Chemical structure of LY2835219

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
500mg	300	In-stock
1g	450	In-stock
5g	1385	In-stock
10g	2185	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	Abemaciclib free base
CAS No.	1231929-97-7
Purity	>99%
Formula	C27H32F2N8
Mol Weight	506.5934
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Oncotarget. 2016 Mar 22;7(12):14803-13; [2]. Biochem Pharmacol. 2017 Jan 15;124:29-42.
CoA	CoA of LY2835219

Smiles:	CCN1CCN(CC2=CN=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)C=C2)CC1


		Search